Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pacmilimab + praluzatamab ravtansine
- Development stage
- Discontinued
- Lead developer
- CytomX
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Pacmilimab + praluzatamab ravtansine is a combination of two conditionally activated antibody-based cancer therapeutics developed by CytomX Therapeutics. Pacmilimab (CX-072) is a Probody therapeutic targeting PD-L1, designed to be activated specifically in the tumor microenvironment by tumor-associated proteases, thereby reducing systemic toxicity. Praluzatamab ravtansine (CX-2009) is a conditionally activated antibody-drug conjugate (ADC) that targets CD166 and delivers the cytotoxic agent DM4 via a protease-cleavable linker and peptide mask. This combination was evaluated in clinical trials for advanced triple-negative breast cancer (TNBC), aiming to leverage immune checkpoint inhibition with targeted cytotoxic delivery[1][3][5]. The development of this combination in TNBC was discontinued after failing to meet efficacy endpoints in Phase 2 studies[5][6].
- Brand names
- praluzatamab ravtansinepacmilimab
- Other names
- pacmilimab + CX-2009CX-072 + praluzatamab ravtansinepacmilimab + DM4-conjugated anti-CD166 ADC
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)ALCAM (Activated leukocyte cell adhesion molecule)
Beyond the preview
Go deeper on pacmilimab + praluzatamab ravtansine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pacmilimab + praluzatamab ravtansine.